Voyager Current Deferred Revenue vs Net Receivables Analysis

VYGR Stock

USD 5.43 0.07 1.31%

Voyager Therapeutics financial indicator trend analysis is much more than just breaking down Voyager Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Voyager Therapeutics is a good investment. Please check the relationship between Voyager Therapeutics Current Deferred Revenue and its Net Receivables accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Voyager Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Voyager Stock, please use our How to Invest in Voyager Therapeutics guide.

Current Deferred Revenue vs Net Receivables

Current Deferred Revenue vs Net Receivables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Voyager Therapeutics Current Deferred Revenue account and Net Receivables. At this time, the significance of the direction appears to have weak relationship.

The correlation between Voyager Therapeutics' Current Deferred Revenue and Net Receivables is 0.3. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Voyager Therapeutics, assuming nothing else is changed. The correlation between historical values of Voyager Therapeutics' Current Deferred Revenue and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Voyager Therapeutics are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Current Deferred Revenue i.e., Voyager Therapeutics' Current Deferred Revenue and Net Receivables go up and down completely randomly.

Correlation Coefficient

0.3

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Net Receivables

Most indicators from Voyager Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Voyager Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Voyager Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Voyager Stock, please use our How to Invest in Voyager Therapeutics guide.At this time, Voyager Therapeutics' Tax Provision is relatively stable compared to the past year. As of 11/22/2024, Issuance Of Capital Stock is likely to grow to about 32.7 M, while Sales General And Administrative To Revenue is likely to drop 0.14.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	111.0M	91.7M	35.8M	34.0M
Cost Of Revenue	73.8M	6.2M	92.2M	61.1M

Total Operating Expenses Cost Of Revenue

Voyager Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Total Liab	Total Current Assets	Short Term Debt	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Common Stock Total Equity	Short Term Investments	Other Current Assets	Other Stockholder Equity	Deferred Long Term Liab
Total Assets		0.79	0.93	0.78	0.82	-0.79	-0.73	0.38	0.75	0.78	0.44	0.51	0.98	0.81	0.77	0.85	0.99	-0.04	0.52	0.79	0.67	0.92	-0.17	0.57	0.79	0.25
Short Long Term Debt Total	0.79		0.72	0.51	0.64	-0.83	-0.7	0.01	0.79	0.81	0.66	0.8	0.81	0.72	0.64	0.66	0.74	0.18	0.45	0.9	0.69	0.85	-0.5	0.53	0.69	0.39
Other Current Liab	0.93	0.72		0.8	0.66	-0.77	-0.81	0.52	0.78	0.76	0.52	0.59	0.87	0.87	0.85	0.91	0.91	0.02	0.59	0.63	0.77	0.88	-0.2	0.61	0.88	0.23
Total Current Liabilities	0.78	0.51	0.8		0.49	-0.84	-0.89	0.67	0.83	0.73	0.52	0.44	0.71	0.8	0.66	0.85	0.75	-0.05	0.39	0.41	0.72	0.82	-0.4	0.64	0.84	-0.06
Total Stockholder Equity	0.82	0.64	0.66	0.49		-0.61	-0.51	0.03	0.54	0.59	0.08	0.18	0.8	0.61	0.39	0.47	0.82	-0.07	0.08	0.79	0.45	0.76	-0.18	0.47	0.59	0.31
Net Debt	-0.79	-0.83	-0.77	-0.84	-0.61		0.95	-0.29	-0.96	-0.85	-0.66	-0.7	-0.74	-0.9	-0.58	-0.74	-0.73	-0.1	-0.29	-0.69	-0.81	-0.94	0.72	-0.75	-0.9	-0.19
Retained Earnings	-0.73	-0.7	-0.81	-0.89	-0.51	0.95		-0.45	-0.94	-0.8	-0.61	-0.64	-0.66	-0.92	-0.64	-0.8	-0.68	-0.09	-0.34	-0.5	-0.84	-0.9	0.68	-0.78	-0.95	-0.07
Accounts Payable	0.38	0.01	0.52	0.67	0.03	-0.29	-0.45		0.32	0.27	0.32	0.17	0.35	0.37	0.61	0.69	0.38	-0.13	0.55	-0.03	0.32	0.29	0.14	0.18	0.38	-0.16
Cash	0.75	0.79	0.78	0.83	0.54	-0.96	-0.94	0.32		0.93	0.6	0.74	0.67	0.88	0.6	0.75	0.68	0.23	0.27	0.61	0.94	0.88	-0.71	0.84	0.9	0.05
Non Current Assets Total	0.78	0.81	0.76	0.73	0.59	-0.85	-0.8	0.27	0.93		0.46	0.68	0.72	0.73	0.64	0.74	0.7	0.25	0.31	0.7	0.93	0.8	-0.53	0.79	0.75	-0.07
Non Currrent Assets Other	0.44	0.66	0.52	0.52	0.08	-0.66	-0.61	0.32	0.6	0.46		0.83	0.49	0.59	0.52	0.57	0.42	0.17	0.53	0.47	0.46	0.58	-0.45	0.2	0.56	0.5
Other Assets	0.51	0.8	0.59	0.44	0.18	-0.7	-0.64	0.17	0.74	0.68	0.83		0.51	0.65	0.57	0.57	0.45	0.24	0.48	0.6	0.7	0.63	-0.54	0.54	0.64	0.41
Cash And Short Term Investments	0.98	0.81	0.87	0.71	0.8	-0.74	-0.66	0.35	0.67	0.72	0.49	0.51		0.72	0.77	0.82	0.98	-0.1	0.59	0.86	0.56	0.88	-0.11	0.43	0.69	0.32
Common Stock Shares Outstanding	0.81	0.72	0.87	0.8	0.61	-0.9	-0.92	0.37	0.88	0.73	0.59	0.65	0.72		0.62	0.76	0.78	0.2	0.33	0.56	0.79	0.92	-0.54	0.75	0.97	0.28
Non Current Liabilities Total	0.77	0.64	0.85	0.66	0.39	-0.58	-0.64	0.61	0.6	0.64	0.52	0.57	0.77	0.62		0.96	0.75	-0.04	0.89	0.49	0.62	0.65	0.0	0.34	0.61	0.06
Total Liab	0.85	0.66	0.91	0.85	0.47	-0.74	-0.8	0.69	0.75	0.74	0.57	0.57	0.82	0.76	0.96		0.83	-0.04	0.78	0.52	0.71	0.78	-0.16	0.49	0.76	0.03
Total Current Assets	0.99	0.74	0.91	0.75	0.82	-0.73	-0.68	0.38	0.68	0.7	0.42	0.45	0.98	0.78	0.75	0.83		-0.1	0.54	0.77	0.59	0.89	-0.08	0.5	0.75	0.3
Short Term Debt	-0.04	0.18	0.02	-0.05	-0.07	-0.1	-0.09	-0.13	0.23	0.25	0.17	0.24	-0.1	0.2	-0.04	-0.04	-0.1		-0.15	-0.01	0.28	0.0	-0.27	0.14	0.06	-0.12
Other Liab	0.52	0.45	0.59	0.39	0.08	-0.29	-0.34	0.55	0.27	0.31	0.53	0.48	0.59	0.33	0.89	0.78	0.54	-0.15		0.33	0.26	0.37	0.24	-0.03	0.3	0.12
Net Tangible Assets	0.79	0.9	0.63	0.41	0.79	-0.69	-0.5	-0.03	0.61	0.7	0.47	0.6	0.86	0.56	0.49	0.52	0.77	-0.01	0.33		0.5	0.78	-0.3	0.4	0.52	0.48
Property Plant And Equipment Net	0.67	0.69	0.77	0.72	0.45	-0.81	-0.84	0.32	0.94	0.93	0.46	0.7	0.56	0.79	0.62	0.71	0.59	0.28	0.26	0.5		0.74	-0.59	0.86	0.84	-0.06
Common Stock Total Equity	0.92	0.85	0.88	0.82	0.76	-0.94	-0.9	0.29	0.88	0.8	0.58	0.63	0.88	0.92	0.65	0.78	0.89	0.0	0.37	0.78	0.74		-0.51	0.7	0.92	0.3
Short Term Investments	-0.17	-0.5	-0.2	-0.4	-0.18	0.72	0.68	0.14	-0.71	-0.53	-0.45	-0.54	-0.11	-0.54	0.0	-0.16	-0.08	-0.27	0.24	-0.3	-0.59	-0.51		-0.65	-0.58	-0.04
Other Current Assets	0.57	0.53	0.61	0.64	0.47	-0.75	-0.78	0.18	0.84	0.79	0.2	0.54	0.43	0.75	0.34	0.49	0.5	0.14	-0.03	0.4	0.86	0.7	-0.65		0.8	-0.11
Other Stockholder Equity	0.79	0.69	0.88	0.84	0.59	-0.9	-0.95	0.38	0.9	0.75	0.56	0.64	0.69	0.97	0.61	0.76	0.75	0.06	0.3	0.52	0.84	0.92	-0.58	0.8		0.24
Deferred Long Term Liab	0.25	0.39	0.23	-0.06	0.31	-0.19	-0.07	-0.16	0.05	-0.07	0.5	0.41	0.32	0.28	0.06	0.03	0.3	-0.12	0.12	0.48	-0.06	0.3	-0.04	-0.11	0.24

Click cells to compare fundamentals

Voyager Therapeutics Account Relationship Matchups

Voyager Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	354.8M	261.6M	193.9M	159.4M	351.3M	211.3M
Other Current Liab	21.5M	14.2M	11.0M	7.8M	16.8M	10.4M
Total Current Liabilities	76.0M	26.8M	51.0M	72.6M	64.5M	38.3M
Total Stockholder Equity	99.5M	154.3M	95.1M	59.0M	236.3M	248.1M
Net Debt	(51.9M)	(56.8M)	(73.3M)	(75.8M)	(48.5M)	(50.9M)
Retained Earnings	(312.6M)	(275.9M)	(347.1M)	(393.5M)	(261.2M)	(274.2M)
Accounts Payable	4.1M	634K	574K	2.6M	1.6M	1.5M
Cash	86.0M	104.4M	117.4M	99.0M	68.8M	62.9M
Non Current Assets Total	50.1M	63.8M	57.2M	34.9M	31.6M	31.2M
Non Currrent Assets Other	1.7M	537K	1.8M	1.5M	(1.0)	(0.95)
Other Assets	1.7M	2.3M	1.8M	1.5M	1.0	0.95
Cash And Short Term Investments	281.5M	181.1M	132.5M	118.8M	230.9M	167.6M
Common Stock Shares Outstanding	35.9M	37.3M	37.7M	38.4M	44.6M	29.7M
Liabilities And Stockholders Equity	354.8M	261.6M	193.9M	159.4M	351.3M	211.3M
Non Current Liabilities Total	179.2M	80.5M	47.8M	27.7M	50.5M	60.7M
Total Liab	255.2M	107.3M	98.8M	100.3M	115.0M	98.6M
Total Current Assets	304.7M	197.8M	136.7M	124.5M	319.7M	180.1M
Other Liab	148.3M	37.1M	9.2M	7.5M	8.6M	8.1M
Net Tangible Assets	99.5M	154.3M	95.1M	59.0M	67.9M	106.6M
Property Plant And Equipment Net	46.5M	61.5M	55.4M	33.3M	30.0M	29.0M
Short Term Investments	195.5M	76.7M	15.1M	19.9M	162.1M	94.4M
Other Current Assets	2.0M	6.9M	3.4M	5.0M	4.4M	2.8M
Other Stockholder Equity	412.2M	430.3M	442.3M	452.7M	497.5M	339.2M
Property Plant And Equipment Gross	46.5M	25.4M	71.3M	50.5M	45.0M	30.3M
Accumulated Other Comprehensive Income	(104K)	(134K)	(138K)	(219K)	(48K)	(50.4K)
Property Plant Equipment	46.5M	25.4M	21.9M	17.9M	20.5M	18.2M
Current Deferred Revenue	47.2M	7.7M	42.1M	65.8M	42.9M	31.3M
Net Receivables	19.0M	8.0M	748K	639K	84.5M	88.7M
Retained Earnings Total Equity	(312.6M)	(275.9M)	(347.1M)	(393.5M)	(354.2M)	(371.9M)
Capital Surpluse	412.2M	430.3M	442.3M	452.7M	520.6M	384.1M
Inventory	2.2M	6.9M	1.7M	779K	1.0	1.05
Net Invested Capital	99.5M	154.3M	95.1M	59.0M	236.3M	129.6M
Net Working Capital	228.6M	171.0M	85.7M	51.9M	255.2M	267.9M

Pair Trading with Voyager Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Voyager Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Voyager Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Voyager Stock

0.38	RNXT	RenovoRx	Pair Corr
0.38	KEP	Korea Electric Power	Pair Corr

The ability to find closely correlated positions to Voyager Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Voyager Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Voyager Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Voyager Therapeutics to buy it.

The correlation of Voyager Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Voyager Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Voyager Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Voyager Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Voyager Stock Analysis

When running Voyager Therapeutics' price analysis, check to measure Voyager Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyager Therapeutics is operating at the current time. Most of Voyager Therapeutics' value examination focuses on studying past and present price action to predict the probability of Voyager Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyager Therapeutics' price. Additionally, you may evaluate how the addition of Voyager Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC